this The study was announced It has been posted on medRxiv.org as a preprint and has not yet been peer reviewed. Important point A review of...
The US Food and Drug Administration (FDA) has approved a weekly 2.4 mg subcutaneous dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy, Novo Nordisk)...
Editor’s Note: Find the latest COVID-19 news and guidance from Medscape Coronavirus Resource Center.. New findings suggest that the ability to initiate a humoral immune response...
Phase 3a Step 1 study investigating the use of Semaglutide (Novo Nordisk), a glucagon-like peptide-1 (GLP-1) agonist, some say it has been properly named for weight...
Editor’s Note: Find the latest COVID-19 news and guidance from Medscape Coronavirus Resource Center. Neither diabetes itself nor hyperglycemia appears to impair the antibody response to...
A new study linked anxiety disorders with thyroid autoimmune inflammation. New study presented at European Endocrine Society e-ECE 2020 Digital conference. Dr. Juliya Onofriichuk and her...
Recent Comments